Cannabidiol for drop seizures in Lennox-Gastaut syndrome

Affiliations

Comment

Sophia Varadkar. Lancet. 2018.

. 2018 Mar 17;391(10125):1006-1007.

doi: 10.1016/S0140-6736(18)30135-1. Epub 2018 Jan 26.

¹ Neuroscience Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK. Electronic address: sophia.varadkar@gosh.nhs.uk.

No abstract available

Comment on

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group. Thiele EA, et al. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. Lancet. 2018. PMID: 29395273 Clinical Trial.